Subscribe
tumsasedgars
tumsasedgars / iStockphoto.com
24 July 2018Americas

PTAB shoots down tenth I-MAK Gilead challenge

The Patent Trial and Appeal Board (PTAB) has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Patent abuse driving high drug prices, non-profit claims
2 August 2018   Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.
Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Patent abuse driving high drug prices, non-profit claims
2 August 2018   Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.
Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

More on this story

Americas
Patent abuse driving high drug prices, non-profit claims
2 August 2018   Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.
Asia
AbbVie faces hepatitis C patent challenge in India
26 July 2018   In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
Americas
PTAB rejects IPR challenges to Gilead patents
14 June 2018   The Patent Trial and Appeal Board has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler